Cleared Traditional

K771263 - RADIOMHTER OSM-2 HEMOXIMETER

K771263 is the FDA 510(k) clearance for RADIOMHTER OSM-2 HEMOXIMETER by The London Co.. It is a Class 2 Hematology device (product code GHS) cleared through the Traditional 510(k) pathway after a 23-day FDA review.

K771263 · The London Co. · Hematology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Aug 1977
Decision
23d
Days
Class 2
Risk

K771263 is an FDA 510(k) clearance for the RADIOMHTER OSM-2 HEMOXIMETER. Classified as Assay, Carboxyhemoglobin (product code GHS), Class II - Special Controls.

Submitted by The London Co. (Mchenry, US). The FDA issued a Cleared decision on August 3, 1977 after a review of 23 days - a notably fast clearance cycle.

This device falls under the Hematology FDA review panel, regulated under 21 CFR 864.7425 - the FDA hematology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all The London Co. devices

Submission Details

510(k) Number K771263 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received July 11, 1977
Decision Date August 03, 1977
Days to Decision 23 days
Submission Type Traditional
Review Panel Hematology (HE)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
90d faster than avg
Panel avg: 113d · This submission: 23d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code GHS Assay, Carboxyhemoglobin
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 864.7425
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Hematology devices follow this clearance model.